In the present study, a novel, fast, sensitive and robust method to quantify clozapine in human plasma using quetiapine as the internal standard (IS) is described. The analyte and the IS were extracted from plasma using a single protein precipitation extraction technique with methanol and analyzed by high performance liquid chromatography coupled to the electrospray ionization tandem mass spectrometric (HPLC-ESI-MS/MS). The method was linear over the range 20 to 1500 ng.mL-1. The intra-assay precisions ranged from 3.8 to 5.9%, while inter-assay precisions ranged from 4.2 to 6.0%. The intra-assay accuracies ranged from 99.3 to 107.5%, while the inter-assay accuracies ranged from 98.9 to 101.7%. This method agrees with the requirements proposed by the US Food and Drug Administration of high sensitivity, specificity and high sample throughput and was used to evaluate the pharmacokinetic profiles and bioequivalence of the two clozapine formulations in twenty six schizophrenic patients affected by refractory schizophrenia under steady-state conditions. During the hospitalization period the patients received the 100 mg clozapine formulation tablets corresponding to the same dose they were using 14 days before hospitalization. The clozapine pharmacokinetic did not differ significantly after administration of both test and the reference formulations. The Tmax and T1/2 for the test formulation were 2.26 and 10.92 h, respectively. In addition, the Tmax and T1/2 for the reference formulation were 2.44 and 11.08 h, respectively. The 90% confidence interval of the mean ratio of lnAUC0-t was within 0.80-1.25 range which indicates that the test formulation was bioequivalent to the reference formulation when orally administered to schizophrenic patients regarding both the rate and extent of absorption. © 2012 Bentham Science Publishers.74241253Lieberman, J.A., Safferman, A.Z., Clinical profile of clozapine: Adverse reactions and agranulocytosis (1992) Psychiatr Q, 63, pp. 51-70Senn, H.J., Jungi, W.F., Kunz, H., Poldinger, W., Clozapine and agranulocytosis (1977) Lancet, 1, p. 547Kane, J., Honigfeld, G., Singer, J., Meltzer, H., Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine (1988) Arch Gen Psychiatry, 45, pp. 789-796Meltzer, H.Y., Treatment-resistant schizophrenia--the role of clozapine (1997) Curr Med Res Opin, 14, pp. 1-20Jann, M.W., Grimsley, S.R., Gray, E.C., Chang, W.H., Pharmacokinetics and pharmacodynamics of clozapine (1993) Clin Pharmacokinet, 24, pp. 161-176Mauri, M.C., Volonteri, L.S., Colasanti, A., Fiorentini, A., de Gaspari, I.F., Bareggi, S.R., Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response (2007) Clin Pharmacokinet, 46, pp. 359-388Raedler, T.J., Hinkelmann, K., Wiedemann, K., Variability of the in vivo metabolism of clozapine (2008) Clin Neuropharmacol, 31, pp. 347-352Baldessarini, R.J., Frankenburg, F.R., Clozapine. A novel antipsychotic agent (1991) N Engl J Med, 324, pp. 746-754Centorrino, F., Baldessarini, R.J., Kando, J.C., Frankenburg, F.R., Volpicelli, S.A., Flood, J.G., Clozapine and metabolites: Concentrations in serum and clinical findings during treatment of chronically psychotic patients (1994) J Clin Psychopharmacol, 14, pp. 119-125Kurz, M., Hummer, M., Kurzthaler, I., Oberbauer, H., Fleischhacker, W.W., Efficacy of medium-dose clozapine for treatment-resistant schizophrenia (1995) Am J Psychiatry, 152, pp. 1690-1691Lin, S.K., Chang, W.H., Chung, M.C., Lam, Y.W., Jann, M.W., Disposition of clozapine and desmethylclozapine in schizophrenic patients (1994) J Clin Pharmacol, 34, pp. 318-324Guitton, C., Abbar, M., Kinowski, J.M., Chabrand, P., Bressolle, F., Multiple-dose pharmacokinetics of clozapine in patients with chronic schizophrenia (1998) J Clin Psychopharmacol, 18, pp. 470-476Haring, C., Barnas, C., Saria, A., Humpel, C., Fleischhacker, W.W., Doserelated plasma levels of clozapine (1989) J Clin Psychopharmacol, 9, pp. 71-72Haring, C., Fleischhacker, W.W., Schett, P., Humpel, C., Barnas, C., Saria, A., Influence of patient-related variables on clozapine plasma levels (1990) Am J Psychiatry, 147, pp. 1471-1475Perry, P.J., Bever, K.A., Arndt, S., Combs, M.D., Relationship between patient variables and plasma clozapine concentrations: A dosing nomogram (1998) Biol Psychiatry, 44, pp. 733-738Cheng, Y.F., Lundberg, T., Bondesson, U., Lindstrom, L., Gabrielsson, J., Clinical pharmacokinetics of clozapine in chronic schizophrenic patients (1988) Eur J Clin Pharmacol, 34, pp. 445-449Choc, M.G., Hsuan, F., Honigfeld, G., Single-vs multiple-dose pharmacokinetics of clozapine in psychiatric patients (1990) Pharm Res, 7, pp. 347-351Byerly, M.J., DeVane, C.L., Pharmacokinetics of clozapine and risperidone: A review of recent literature (1996) J Clin Psychopharmacol, 16, pp. 177-187Fang, J., Coutts, R.T., McKenna, K.F., Baker, G.B., Elucidation of individual cytochrome P450 enzymes involved in the metabolism of clozapine (1998) Naunyn Schmiedebergs Arch Pharmacol, 358, pp. 592-599Pirmohamed, M., Williams, D., Madden, S., Templeton, E., Park, B.K., Metabolism and bioactivation of clozapine by human liver in vitro (1995) J Pharmacol Exp Ther, 272, pp. 984-990Dahl, M.L., Llerena, A., Bondesson, U., Lindstrom, L., Bertilsson, L., Disposition of clozapine in man: Lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms (1994) Br J Clin Pharmacol, 37, pp. 71-74Garay, G.L., Forfar-Bares, I., Pehourcq, F., Jarry, C., Simultaneous determination of four antipsychotic drugs in plasma by highperformance liquid chromatography. Application to management of acute intoxications (2003) J Chromatogr B Analyt Technol Biomed Life Sci, 795, pp. 257-264Guitton, C., Kinowski, J.M., Aznar, R., Bressolle, F., Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detection (1997) J Chromatogr B Biomed Sci Appl, 690, pp. 211-222Janiszewski, J.S., Fouda, H.G., Cole, R.O., Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography (1995) J Chromatogr B Biomed Appl, 668, pp. 133-139Liu, Y.Y., van Troostwijk, L.J., Guchelaar, H.J., Simultaneous determination of clozapine, norclozapine and clozapine-N-oxide in human plasma by high-performance liquid chromatography with ultraviolet detection (2001) Biomed Chromatogr, 15, pp. 280-286Llerena, A., Berecz, R., Norberto, M.J., de la Rubia, A., Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection (2001) J Chromatogr B Biomed Sci Appl, 755, pp. 349-354Mosier, K.E., Song, J., McKay, G., Hubbard, J.W., Fang, J., Determination of clozapine, and its metabolites, N-desmethylclozapine and clozapine N-oxide in dog plasma using high-performance liquid chromatography (2003) J Chromatogr B Analyt Technol Biomed Life Sci, 783, pp. 377-382Sachse, J., Koller, J., Hartter, S., Hiemke, C., Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection (2006) J Chromatogr B Analyt Technol Biomed Life Sci, 830, pp. 342-348Weigmann, H., Bierbrauer, J., Hartter, S., Hiemke, C., Automated determination of clozapine and major metabolites in serum and urine (1997) Ther Drug Monit, 19, pp. 480-488Weigmann, H., Hiemke, C., Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection (1992) J Chromatogr, 583, pp. 209-216Raggi, M.A., Bugamelli, F., Mandrioli, R., Sabbioni, C., Volterra, V., Fanali, S., Rapid capillary electrophoretic method for the determination of clozapine and desmethylclozapine in human plasma (2001) J Chromatogr A, 916, pp. 289-296Maresova, V., Chadt, J., Novakova, E., Screening and semiquantitative analysis of drugs and drugs of abuse in human serum samples using gas chromatography-mass spectrometry (2008) Neuro Endocrinol Lett, 29, pp. 749-754Maurer, H.H., Advances in analytical toxicology: The current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid (2005) Anal Bioanal Chem, 381, pp. 110-118Niessen, W.M., Progress in liquid chromatography-mass spectrometry instrumentation and its impact on high-throughput screening (2003) J Chromatogr A, 1000, pp. 413-436Aravagiri, M., Marder, S.R., Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients (2001) J Pharm Biomed Anal, 26, pp. 301-311Kirchherr, H., Kuhn-Velten, W.N., Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach (2006) J Chromatogr B Analyt Technol Biomed Life Sci, 843, pp. 100-113Ming, D.S., Heathcote, J., Therapeutic drug monitoring of clozapine and norclozapine in human serum using ultra-performance liquid chromatography-tandem mass spectrometry (2009) J Anal Toxicol, 33, pp. 198-203Wang, X.Q., Pan, X.J., Lin, G.Y., Simultaneous determination of clozapine, olanzapine and mirtazapine in human plasma by LCMS/ MS (2009) Fa Yi Xue Za Zhi, 25, pp. 123-126Zhang, G., Terry Jr., A.V., Bartlett, M.G., Liquid chromatography/ tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma (2007) Rapid Commun Mass Spectrom, 21, pp. 920-928Zhang, G., Terry Jr., A.V., Bartlett, M.G., Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue (2007) J Chromatogr B Analyt Technol Biomed Life Sci, 858, pp. 276-281Zhou, Z., Li, X., Li, K., Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by highperformance liquid chromatography-electrospray ionization mass spectrometry (2004) J Chromatogr B Analyt Technol Biomed Life Sci, 802, pp. 257-262Saint-Marcoux, F., Sauvage, F.L., Marquet, P., Current role of LC-MS in therapeutic drug monitoring (2007) Anal Bioanal Chem, 388, pp. 1327-1349Moreno, R.A., Oliveira Costa, I., Brum Junior, L., Cimetidine Quantification in Human Plasma by High-performance Liquid Chromatography Coupled to Electrospray Ionization Tandem Mass Spectrometry. Application to a Comparative Pharmacokinetics Study (2009) J Bioanal & Biomed, 1, p. 9Choong, E., Rudaz, S., Kottelat, A., Guillarme, D., Veuthey, J.L., Eap, C.B., Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS (2009) J Pharm Biomed Anal, 50, pp. 1000-1008Niederlander, H.A., Koster, E.H., Hilhorst, M.J., High throughput therapeutic drug monitoring of clozapine and metabolites in serum by on-line coupling of solid phase extraction with liquid chromatography-mass spectrometry (2006) J Chromatogr B Analyt Technol Biomed Life Sci, 834, pp. 98-107Song, M., Yu, X., Zhao, H., Hang, T., Yang, L., Wei Xu, W., LC-MS-MS Determination and Pharmacokinetic Study of Clozapine in Human Plasma (2009) Chromatographia, 69, pp. 1049-1054Kollroser, M., Schober, C., Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and Ndesmethylclozapine in human plasma (2002) Rapid Commun Mass Spectrom, 16, pp. 1266-1272Baldessarini, R.J., Cohen, B.M., Teicher, M.H., Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses (1988) Arch Gen Psychiatry, 45, pp. 79-91Kluznik, J.C., Walbek, N.H., Farnsworth, M.G., Melstrom, K., Clinical effects of a randomized switch of patients from clozaril to generic clozapine (2001) J Clin Psychiatry, 62 (SUPPL. 5), pp. 14-17. , discussion 23-4Layton, S., Barbeau, M., Generic replacement of clozapine: A simple decision model from a Canadian perspective (2004) Curr Med Res Opin, 20, pp. 453-459Makela, E.H., Cutlip, W.D., Stevenson, J.M., Branded versus generic clozapine for treatment of schizophrenia (2003) Ann Pharmacother, 37, pp. 350-353Mofsen, R., Balter, J., Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation (2001) Clin Ther, 23, pp. 1720-1731Nuss, P., Taylor, D., de Hert, M., Hummer, M., The generic alternative in schizophrenia: Opportunity or threat? (2004) CNS Drugs, 18, pp. 769-775Sajbel, T.A., Carter, G.W., Wiley, R.B., Converting patients from brandname clozapine to generic clozapine (2001) Ann Pharmacother, 35, pp. 281-284Choc, M.G., Lehr, R.G., Hsuan, F., Multiple-dose pharmacokinetics of clozapine in patients (1987) Pharm Res, 4, pp. 402-405Jerling, M., Merle, Y., Mentre, F., Mallet, A., Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method (1997) Br J Clin Pharmacol, 44, pp. 447-453Golden, G., Honigfeld, G., Bioequivalence of clozapine orally disintegrating 100-mg tablets compared with clozapine solid oral 100-mg tablets after multiple doses in patients with schizophrenia (2008) Clin Drug Investig, 28, pp. 231-239Haring, C., Meise, U., Humpel, C., Saria, A., Fleischhacker, W.W., Hinterhuber, H., Dose-related plasma levels of clozapine: Influence of smoking behaviour, sex and age (1989) Psychopharmacology (Berl), 99 (SUPPL.), pp. S38-S40Pokorny, R., Finkel, M.J., Robinson, W.T., Normal volunteers should not be used for bioavailability or bioequivalence studies of clozapine (1994) Pharm Res, 11, p. 1221Guidance for Industry (2005) Clozapine Tablets: In Vivo Bioequivalence and In Vitro Dissolution Testing, , FDATassaneeyakul, W., Kittiwattanagul, K., Vannaprasaht, S., Steady-state bioequivalence study of clozapine tablet in schizophrenic patients (2005) J Pharm Pharm Sci, 8, pp. 47-53Guitton, C., Kinowski, J.M., Abbar, M., Chabrand, P., Bressolle, F., Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia (1999) J Clin Pharmacol, 39, pp. 721-728Oluboka, O., Stewart, S., Landry, S., Adams, S., Does therapeutic equivalence follow bioequivalence? A randomized trial to assess clinical effects after switching from clozaril to generic clozapine (gen-clozapine) (2010) J Clin Pharmacol, 50, pp. 531-535